(Q36764935)

16 August 2017

title

Biological therapies: new treatment options for ANCA-associated vasculitis? (English)

1 reference

16 August 2017

Peer M Aries

1

1 reference

16 August 2017

Peter Lamprecht

series ordinal

2

1 reference

16 August 2017

Wolfgang L Gross

series ordinal

3

1 reference

16 August 2017

language of work or name

English

0 references

publication date

1 April 2007

1 reference

Expert Opinion on Biological Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

4

1 reference

16 August 2017

page(s)

521-533

1 reference

Wegener Granulomatosis: An Analysis of 158 Patients

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

An interdisciplinary approach to the care of patients with Wegener's granulomatosis: long-term outcome in 155 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Advances in the therapy of Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

High rate of renal relapse in 71 patients with Wegener's granulomatosis under maintenance of remission with low-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Autoantigen complementarity: a new theory implicating complementary proteins as initiators of autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Wegener autoantigen induces maturation of dendritic cells and licenses them for Th1 priming via the protease-activated receptor-2 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

B lymphocyte maturation in Wegener's granulomatosis: a comparative analysis of VH genes from endonasal lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Treatment options in metastatic renal carcinoma: an embarrassment of riches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Effector memory T cells as driving force of granuloma formation and autoimmunity in Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Proinflammatory cytokines and autoimmunity in Churg-Strauss syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Pathogenesis of Wegener's granulomatosis: current concepts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

On 'reactivity' versus 'tolerance'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

New indications for treatment of chronic inflammation by TNF-alpha blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Effectiveness of TNF-alpha blockade with infliximab in refractory Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Etanercept plus standard therapy for Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Design of the Wegener's Granulomatosis Etanercept Trial (WGET).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Etanercept for active Crohn's disease: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Rituximab therapy and autoimmune disorders: prospects for anti-B cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Rituximab treatment in patients with primary Sjögren's syndrome: an open-label phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Long-lived plasma cells and their contribution to autoimmunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

The Th1 and Th2 Paradigm in ANCA-Associated Vasculitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Churg-Strauss syndrome: update on recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Leucoencephalopathy after treatment of Churg-Strauss syndrome with interferon {alpha}.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

Binding and Functional Comparisons of Two Types of Tumor Necrosis Factor Antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.7.4.521

21 January 2018

Identifiers

DOI

10.1517/14712598.7.4.521

1 reference

16 August 2017

1 reference